Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
The world is less than a week into 2019 and already universities are proving they have every intention of building and expanding on the historic successes of the past 12 months – stay tuned for the annual data review in this month’s magazine.
There is Friday’s acquisition of CoreBiome, a US-based genomic and informatics technology spinout of University of Michigan by point-of-care diagnostics devices manufacturer OraSure Technologies, less than 18 months after the spinout’s formation.
There is Cabaletta Bio,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
